| abstract |
The present invention relates to an antibody-drug conjugate in which a modified antibody comprising a motif of a specific structure at the terminal of the antibody is bound to a drug through a linker, and a composition comprising the same. More specifically, A modified Antibody-Drug Conjugate (mADC) conjugate comprising a modified antibody having a significantly increased conjugation yield, and a composition comprising the same. |